Acumen Pharmaceuticals Inc 2026年季度报告

FORM 10-Q___________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40551___________________________ Acumen Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter)___________________________ Delaware36-4108129(State or other jurisdiction of(I.R.S. Employer incorporation or organization)Identification No.) (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: (617) 344-4190___________________________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNoAs of May7, 2026, the registrant had 72,227,580 shares of common stock, par value $0.0001 per share, outstanding. Table of Contents PagePART I.FINANCIAL INFORMATION4Item 1.Financial Statements (Unaudited)4Condensed Balance Sheets4Condensed Statements of Operations and Comprehensive Loss5Condensed Statements of Changes in Stockholders’ Equity6Condensed Statements of Cash Flows7Notes to Condensed Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations22Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures30PART II.OTHER INFORMATION31Item 1.Legal Proceedings31Item 1A.Risk Factors31Item 2.Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities31Item 3.Defaults Upon Senior Securities31Item 4.Mine Safety Disclosures31Item 5.Other Information31Item 6.Exhibits32Signatures33 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the Private Securities LitigationReform Act of 1995, about us and our industry that involve substantial risks and uncertainties. All statements other than statements ofhistorical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations orfinancial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements.In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,”“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or“would” or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are notlimited to, statements concerning the following: •the sufficiency of our existing cash and cash equivalents and marketable securities to fund our future operating expensesand capital expenditure requirements;•our ability to obtain funding for our operations, including funding necessary to develop and commercialize sabirnetug orany Aß oligomer-targeted Enhanced Brain Delivery (EBD™) product candidates that we may develop pursuant to ourcollaboration with JCR Pharmaceuticals Co. Ltd., subject to obtaining necessary regulatory approvals, and our ability tocontinue as a going concern;•the ability of our clinical trials to demonstrate the safety and efficacy of sabirnetug, and other positive results;•the therapeutic potential of sabirnetug, including its potential for improved safety and efficacy as compared to othermonoclonal antibodies approved and/or in development, and an Aß oligomer-targeted EBD therapy for Alzheimer’sdisease, a